CNBC August 16, 2024
Key Points
– Danish biotech company Bavarian Nordic said Friday that it had submitted data to the European Union’s drug regulator to extend the use of its mpox vaccine for teenagers.
– CEO Paul Chaplin told CNBC that the expanded approval for 12- to 17-year-olds would be crucial in tackling the latest outbreak, which particularly afflicts teenagers and young children.
– It comes after the WHO on Wednesday declared an escalating mpox outbreak in Africa a public health emergency.
LONDON — Danish biotech company Bavarian Nordic said Friday that it had submitted data to the European Union’s drug regulator to extend the use of its mpox vaccine for teenagers.
CEO Paul Chaplin told CNBC that the expanded approval for 12...
Today's Sponsors
Today's Sponsor